Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Trade-press coverage of Lilly acquiring the exclusive worldwide AXIRON license, described as the biggest-ever Australian biotech licensing arrangement at up to…
CosmeticsDesign-Asia framed the deal as Australian biotech Acrux securing a global commercialization partner for its differentiated underarm testosterone…
FDA confirmed Lilly requested withdrawal of the Axiron NDA in September 2017 and that the product was 'not withdrawn from sale for reasons of safety or…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Lilly entered exclusive worldwide license with Acrux for AXIRON: $50M upfront + $3M manufacturing transfer + $87M FDA marketing approval + $195M commercialization milestones, plus royalties.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Acrux Limited (AXIRON license) (this deal) | 2010 | $335M | — |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2010 deals · Eli Lilly and Company deals · Metabolic deals